Home Newsfeeds JP Morgan Downgrades Bioventus to Underweight

JP Morgan Downgrades Bioventus to Underweight

JP Morgan analyst Robbie Marcus downgrades Bioventus (NASDAQ:BVS) from Overweight to Underweight.

byBenzinga Newsdesk

November 9, 2022

1 minute read

JP Morgan analyst Robbie Marcus downgrades Bioventus (NASDAQ:BVS) from Overweight to Underweight.

UNITY Biotechnology Announces Proposed Public Offering of Common Stock

By Benzinga Newsdesk

August 16, 4:02 PM

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging,

UBX

This Analyst Sees Recovery For PolyPid Despite Failed Phase 3 Readout

By Vandana Singh

September 6, 3:25 PM

Raymond James downgraded PolyPid Ltd (NASDAQ:PYPD) from Strong Buy to Outperform post SHIELD I Phase 3 results that, despite consistency and evidence of…

PYPD

RenovoRx Engages Oklahoma University Health As First Clinical Site In Preparation For The Pivotal Phase III CouGar Clinical Trial In Bile Duct Cancer

By Benzinga Newsdesk

December 21, 9:33 AM

This study will be the Second Clinical Trial Evaluating RenovoGem™, a Combination Drug-Device Product, in a Difficult-to-Access Solid Tumor CancerRenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a

RNXT

Bezos Wants To Be Musk So Bad: A Cosmic Rivalry Turned 69/420?

By AJ Fabino

May 30, 2:43 PM

In the realm of tech moguls, few rivalries resonate as strongly as that of Jeff Bezos and Elon…

AMZN

JP Morgan Downgrades Bioventus to Underweight

Related Posts

UNITY Biotechnology Announces Proposed Public Offering of Common Stock

This Analyst Sees Recovery For PolyPid Despite Failed Phase 3 Readout

RenovoRx Engages Oklahoma University Health As First Clinical Site In Preparation For The Pivotal Phase III CouGar Clinical Trial In Bile Duct Cancer

Bezos Wants To Be Musk So Bad: A Cosmic Rivalry Turned 69/420?